guidesFebruary 21, 2026·5 min read

DSIP Dosing: 250mcg Before Bed Protocol

Most miss the 5-on/2-off cycling that prevents tolerance. Covers 250mcg timing, reconstitution, and Selank/Epitalon stacking.

DSIP Dosing: 250mcg Before Bed Protocol

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit brain in 1977, named for its ability to promote slow-wave (delta) sleep. Research has since revealed a broader profile including stress-hormone modulation, neuroendocrine regulation, and potential applications in substance withdrawal. DSIP is not FDA-approved. This is not medical advice.

Quick Reference: Standard Protocol

Parameter Standard Protocol
Dose 250 mcg
Route Subcutaneous injection
Timing 1-3 hours before bed
Frequency 5 days on, 2 days off
Cycle 8 weeks on, 8 weeks off
Vial size 5 mg
Reconstitution 2 mL bacteriostatic water → 2,500 mcg/mL
Draw amount 10 units on insulin syringe
Storage Refrigerate 2-8°C, use within 28 days

Standard protocol: 250 mcg subcutaneous, 1-3 hours before bed, 5 days on / 2 days off, for 8-week cycles.

For the full DSIP peptide profile, see our DSIP peptide page.

Cycling: 8 Weeks On, 8 Weeks Off

Run 250 mcg nightly (5 on / 2 off) for 8 weeks, then take 8 weeks off. DSIP's documented delayed effects -- where sleep improvements persist beyond the active dosing period -- mean the off-cycle period is often still beneficial.

While no clinical evidence demonstrates DSIP tolerance development, cycling maintains receptor sensitivity and allows you to monitor residual effects during the off period.

Enhanced Protocol (Community)

Some practitioners reference alternative cycling patterns:

Dr. Seeds protocol: 100 mcg subcutaneously at night, administered daily, every 3 days, or weekly depending on individual response.

Pulse protocol: 100-200 mcg nightly for 10 consecutive days, followed by 20 days off. This leverages DSIP's delayed effects where improvements persist beyond active dosing.

The 250 mcg / 5-on / 2-off standard from the cheat sheet is the recommended starting point. These alternatives reflect community variations.

Routes of Administration

Subcutaneous injection (standard): Inject into abdominal area (2+ inches from navel), thigh, or upper arm. Use 29-31 gauge insulin syringe. Rotate injection sites.

Clinical context: Early studies used IV infusions at 25 nmol/kg with morning timing and still observed delayed sleep benefits, but evening SC injection is the community standard.

Reconstitution Quick Reference

Vial Size BAC Water Concentration 250 mcg Dose
5 mg 2 mL 2,500 mcg/mL 10 units

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. For 250 mcg: 250 / 2,500 = 0.1 mL = 10 units. One vial lasts 20 doses.

Swirl gently -- do not shake. Refrigerate at 2-8°C and use within 28 days. For step-by-step instructions, see the Reconstitution Calculator.

DSIP Reconstitution Guide

Where These Numbers Come From

DSIP's research spans over 40 years, though many studies are small-scale by modern standards.

Sleep studies: Schneider-Helmert (1981) administered 25 nmol/kg IV to healthy volunteers and observed enhanced delta sleep with delayed onset of effects. A 1992 double-blind study in 16 chronic insomnia patients found improved subjective sleep quality vs placebo (PMID: 1299794).

Stress and withdrawal: DSIP attenuates basal and stress-induced ACTH release, dampening the cortisol stress response. Dick et al. (1984) successfully treated withdrawal symptoms in opiate- and alcohol-dependent patients (PMID: 6548969).

Safety profile: Pollard & Pomfrett (2001) described DSIP as "incredibly safe" in a comprehensive review -- no lethal dose identified in animal studies, no significant adverse effects beyond transient headache, nausea, and vertigo in humans.

Neuroprotection: A 2021 study showed DSIP accelerated motor function recovery in rats following focal stroke, suggesting applications beyond sleep.

Stacking Protocols

Stack Components Purpose
Anxiolytic Sleep DSIP 250 mcg + Selank 200-400 mcg intranasal Delta sleep + GABA-modulatory anxiolysis
Sleep + Longevity DSIP 250 mcg + Epitalon 2 mg Delta wave promotion + pineal melatonin
Sleep + Recovery DSIP 250 mcg + Ipamorelin 100-200 mcg Deep sleep + GH release during sleep

Inject stacked peptides at separate sites. Do not mix in the same syringe unless validated for compatibility.

Side Effects & Safety

  • Transient headache -- the most commonly reported side effect
  • Mild nausea -- usually resolves within 30 minutes
  • Temporary dizziness/vertigo -- reported at higher doses
  • Injection site redness -- standard for SC peptides
  • No lethal dose identified in animal studies
  • No dependency or withdrawal documented
  • No respiratory depression -- unlike pharmaceutical sleep aids

DSIP appears on the FDA's list of bulk drug substances with potential safety concerns, reflecting regulatory conservatism around limited human data rather than documented toxicity.

Frequently Asked Questions

What is the standard DSIP dose?

250 mcg subcutaneously, 1-3 hours before bed, 5 days on / 2 days off, cycled 8 weeks on / 8 weeks off. Use a 5 mg vial with 2 mL BAC water -- 250 mcg equals 10 units.

How long does it take for DSIP to work?

Many users report improved sleep within 1-3 nights. Cumulative effects on sleep architecture may take 5-10 days of consistent use.

Can DSIP be used every day?

The standard protocol uses 5 days on / 2 days off. Short-term daily use (10-30 days) appears in some community protocols, but 5 on / 2 off maintains receptor sensitivity.

What is the best time to take DSIP?

1-3 hours before intended sleep. DSIP appears to prime sleep-regulatory circuits rather than acting as an acute sedative.

Does DSIP cause dependency or withdrawal?

No dependency or withdrawal documented. DSIP has itself been studied for treating opiate and alcohol withdrawal symptoms.

Is DSIP FDA-approved?

No. DSIP is a research peptide with no approved human indication.

References

Citation Topic PMID
Graf & Kastin, Neurosci Biobehav Rev (1984) DSIP comprehensive review 6145137
Schneider-Helmert et al., Int J Clin Pharmacol Ther Toxicol (1981) Delta sleep enhancement in healthy volunteers 6895513
Schneider-Helmert, Neuropsychobiology (1992) Double-blind insomnia study 1299794
Dick et al., Eur Neurol (1984) Withdrawal syndrome treatment 6548969
Schneider-Helmert, Eur Neurol (1984) DSIP in narcolepsy 6548968

For educational and research purposes only. This is not medical advice. DSIP is a research peptide not approved by the FDA for human use.